Activating and inhibitory receptors of natural killer cells

Immunology and Cell Biology

Volumn 89, Issue 2, 2011, Pages 216-224

  Pegram, Hollie J ^a   Andrews, Daniel M ^a   Smyth, Mark J ^a   Darcy, Phillip K ^a   Kershaw, Michael H ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

co stimulatory receptors; immune response; immunoreceptor tyrosine based inhibitory motif; missing self; stress ligands

Indexed keywords

CD94 ANTIGEN; CO STIMULATORY RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL LECTIN LIKE RECEPTOR G1; LEUKOCYTE IMMUNOGLOBULIN LIKE RECEPTOR; NATURAL CYTOTOXICITY RECEPTOR; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY A; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2C; NATURAL KILLER CELL RECEPTOR NKG2E; NATURAL KILLER CELL RECEPTOR NKRP1; PAIRED IMMUNOGLOBULIN LIKE 2 RECEPTOR; UNCLASSIFIED DRUG;

CELL ACTIVATION; CELLULAR IMMUNITY; CYTOLOGY; HUMAN; IMMUNE RESPONSE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PROTEIN EXPRESSION; REVIEW;

ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; PROTEIN MULTIMERIZATION; RECEPTORS, NATURAL KILLER CELL;

EID: 79951953456     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2010.78     Document Type: Review

References (178)

1. Shearer WT, Rosenblatt HM, Gelman RS, Oyomopito R, Plaeger S, Stiehm ER et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol 2003; 112: 973-980. (Pubitemid 37412068)
2. Comans-Bitter WM, de Groot R, van den Beemd R, Neijens HJ, Hop WC, Groeneveld K et al. Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. J Pediatr 1997; 130: 388-393. (Pubitemid 27492682)
3. Morris MA, Ley K. Trafficking of natural killer cells. Curr Mol Med 2004; 4: 431-438. (Pubitemid 38787011)
4. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990; 76: 2421-2438.
5. Yokoyama WM, Kim S, French AR. The dynamic life of natural killer cells. Annu Rev Immunol 2004; 22: 405-429. (Pubitemid 38680428)
6. Ferlazzo G, Munz C. NK cell compartments and their activation by dendritic cells. J Immunol 2004; 172: 1333-1339. (Pubitemid 38116773)
7. McQueen KL, Parham P. Variable receptors controlling activation and inhibition of NK cells. Curr Opin Immunol 2002; 14: 615-621.
8. Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990; 11: 237-244.
9. Watzl C. The NKG2D receptor and its ligands-recognition beyond the 'missing self'? Microbes Infect 2003; 5: 31-37.
10. Lanier LL, Corliss B, Phillips JH. Arousal and inhibition of human NK cells. Immunol Rev 1997; 155: 145-154. (Pubitemid 27076066)
11. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001; 413: 165-171. (Pubitemid 32867877)
12. Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 2001; 98: 11521-11526. (Pubitemid 32928761)
13. Karre K. Natural killer cell recognition of missing self. Nat Immunol 2008; 9: 477-480. (Pubitemid 351560515)
14. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001; 2: 255-260. (Pubitemid 33706003)
15. Tomasello E, Blery M, Vely F, Vivier E. Signaling pathways engaged by NK cell receptors: double concerto for activating receptors, inhibitory receptors and NK cells. Semin Immunol 2000; 12: 139-147. (Pubitemid 30199278)
16. Yu MC, Su LL, Zou L, Liu Y, Wu N, Kong L et al. An essential function for beta-arrestin 2 in the inhibitory signaling of natural killer cells. Nat Immunol 2008; 9: 898-907.
17. Bryceson YT, Ljunggren HG, Long EO. Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors. Blood 2009; 114: 2657-2666.
18. Peterson ME, Long EO. Inhibitory receptor signaling via tyrosine phosphorylation of the adaptor Crk. Immunity 2008; 29: 578-588.
19. Tassi I, Cella M, Presti R, Colucci A, Gilfillan S, Littman DR et al. NK cell-activating receptors require PKC-theta for sustained signaling, transcriptional activation, and IFN-gamma secretion. Blood 2008; 112: 4109-4116.
20. Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 2006; 107: 159-166. (Pubitemid 43053538)
21. Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 1998; 391: 703-707. (Pubitemid 28113218)
22. Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999; 285: 730-732.
23. Sutherland CL, Chalupny NJ, Schooley K, VandenBos T, Kubin M, Cosman D. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J Immunol 2002; 168: 671-679. (Pubitemid 34049567)
24. Zompi S, Hamerman JA, Ogasawara K, Schweighoffer E, Tybulewicz VL, Di Santo JP et al. NKG2D triggers cytotoxicity in mouse NK cells lacking DAP12 or Syk family kinases. Nat Immunol 2003; 4: 565-572. (Pubitemid 36701340)
25. Billadeau DD, Upshaw JL, Schoon RA, Dick CJ, Leibson PJ. NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nat Immunol 2003; 4: 557-564. (Pubitemid 36701339)
26. Veillette A. NK cell regulation by SLAM family receptors and SAP-related adapters. Immunol Rev 2006; 214: 22-34. (Pubitemid 44707899)
27. Faure M, Long EO. KIR2DL4 (CD158d), an NK cell-activating receptor with inhibitory potential. J Immunol 2002; 168: 6208-6214. (Pubitemid 34620040)
28. Smith KM, Wu J, Bakker AB, Phillips JH, Lanier LL. Ly-49D and Ly-49H associate with mouse DAP12 and form activating receptors. J Immunol 1998; 161: 7-10. (Pubitemid 28285499)
29. Tormo J, Natarajan K, Margulies DH, Mariuzza RA. Crystal structure of a lectin-like natural killer cell receptor bound to its MHC class I ligand. Nature 1999; 402: 623-631. (Pubitemid 129516325)
30. Dam J, Guan R, Natarajan K, Dimasi N, Chlewicki LK, Kranz DM et al. Variable MHC class I engagement by Ly49 natural killer cell receptors demonstrated by the crystal structure of Ly49C bound to H-2K(b). Nat Immunol 2003; 4: 1213-1222. (Pubitemid 37540690)
31. Mason LH, Willette-Brown J, Mason AT, McVicar D, Ortaldo JR. Interaction of Ly-49D+ NK cells with H-2Dd target cells leads to Dap-12 phosphorylation and IFN-gamma secretion. J Immunol 2000; 164: 603-611. (Pubitemid 30043679)
32. Ortaldo JR, Bere EW, Hodge D, Young HA. Activating Ly-49 NK receptors: central role in cytokine and chemokine production. J Immunol 2001; 166: 4994-4999. (Pubitemid 32280711)
33. Silver ET, Gong D, Hazes B, Kane KP. Ly-49W, an activating receptor of nonobese diabetic mice with close homology to the inhibitory receptor Ly-49G, recognizes H-2D(k) and H-2D(d). J Immunol 2001; 166: 2333-2341. (Pubitemid 32173466)
34. Silver ET, Gong DE, Chang CS, Amrani A, Santamaria P, Kane KP. Ly-49P activates NK-mediated lysis by recognizing H-2Dd. J Immunol 2000; 165: 1771-1781. (Pubitemid 30643126)
35. Orihuela M, Margulies DH, Yokoyama WM. The natural killer cell receptor Ly-49A recognizes a peptide-induced conformational determinant on its major histocompatibility complex class I ligand. Proc Natl Acad Sci USA 1996; 93: 11792-11797. (Pubitemid 26347202)
36. Correa I, Raulet DH. Binding of diverse peptides to MHC class I molecules inhibits target cell lysis by activated natural killer cells. Immunity 1995; 2: 61-71.
37. Hanke T, Takizawa H, McMahon CW, Busch DH, Pamer EG, Miller JD et al. Direct assessment of MHC class I binding by seven Ly49 inhibitory NK cell receptors. Immunity 1999; 11: 67-77. (Pubitemid 29359958)
38. Michaelsson J, Achour A, Salcedo M, Kase-Sjostrom A, Sundback J, Harris RA et al. Visualization of inhibitory Ly49 receptor specificity with soluble major histocompatibility complex class I tetramers. Eur J Immunol 2000; 30: 300-307. (Pubitemid 30011792)
39. Doucey MA, Scarpellino L, Zimmer J, Guillaume P, Luescher IF, Bron C et al. Cis association of Ly49A with MHC class I restricts natural killer cell inhibition. Nat Immunol 2004; 5: 328-336. (Pubitemid 38332130)
40. Scarpellino L, Oeschger F, Guillaume P, Coudert JD, Levy F, Leclercq G et al. Interactions of Ly49 family receptors with MHC class I ligands in trans and cis. J Immunol 2007; 178: 1277-1284. (Pubitemid 46154597)
41. Veinotte LL, Wilhelm BT, Mager DL, Takei F. Acquisition of MHC-specific receptors on murine natural killer cells. Crit Rev Immunol 2003; 23: 251-266. (Pubitemid 37549550)
42. Raulet DH, Held W, Correa I, Dorfman JR, Wu MF, Corral L. Specificity, tolerance and developmental regulation of natural killer cells defined by expression of class I-specific Ly49 receptors. Immunol Rev 1997; 155: 41-52. (Pubitemid 27076057)
43. Mehta IK, Wang J, Roland J, Margulies DH, Yokoyama WM. Ly49A allelic variation and MHC class I specificity. Immunogenetics 2001; 53: 572-583. (Pubitemid 33044437)
44. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 2002; 296: 1323-1326. (Pubitemid 34522789)
45. Barten R, Torkar M, Haude A, Trowsdale J, Wilson MJ. Divergent and convergent evolution of NK-cell receptors. Trends Immunol 2001; 22: 52-57. (Pubitemid 32675282)
46. Abi-Rached L, Parham P. Natural selection drives recurrent formation of activating killer cell immunoglobulin-like receptor and Ly49 from inhibitory homologues. J Exp Med 2005; 201: 1319-1332. (Pubitemid 40629074)
47. Colonna M, Samaridis J. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 1995; 268: 405-408.
48. Wagtmann N, Biassoni R, Cantoni C, Verdiani S, Malnati MS, Vitale M et al. Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains. Immunity 1995; 2: 439-449.
49. Chan HW, Kurago ZB, Stewart CA, Wilson MJ, Martin MP, Mace BE et al. DNA methylation maintains allele-specific KIR gene expression in human natural killer cells. J Exp Med 2003; 197: 245-255. (Pubitemid 36152318)
50. Yawata M, Yawata N, Draghi M, Little AM, Partheniou F, Parham P. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med 2006; 203: 633-645.
51. Andersson S, Fauriat C, Malmberg JA, Ljunggren HG, Malmberg KJ. KIR acquisition probabilities are independent of self-HLA class I ligands and increase with cellular KIR expression. Blood 2009; 114: 95-104.
52. Campbell KS, Dessing M, Lopez-Botet M, Cella M, Colonna M. Tyrosine phosphorylation of a human killer inhibitory receptor recruits protein tyrosine phosphatase 1C. J Exp Med 1996; 184: 93-100. (Pubitemid 26247218)
53. Burshtyn DN, Scharenberg AM, Wagtmann N, Rajagopalan S, Berrada K, Yi T et al. Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor. Immunity 1996; 4: 77-85. (Pubitemid 26056459)
54. Lanier LL. NK cell receptors. Annu Rev Immunol 1998; 16: 359-393. (Pubitemid 28183369)
55. Olcese L, Cambiaggi A, Semenzato G, Bottino C, Moretta A, Vivier E. Human killer cell activatory receptors for MHC class I molecules are included in a multimeric complex expressed by natural killer cells. J Immunol 1997; 158: 5083-5086. (Pubitemid 127681207)
56. Hansasuta P, Dong T, Thananchai H, Weekes M, Willberg C, Aldemir H et al. Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur J Immunol 2004; 34: 1673-1679. (Pubitemid 39256049)
57. Malnati MS, Peruzzi M, Parker KC, Biddison WE, Ciccone E, Moretta A et al. Peptide specificity in the recognition of MHC class I by natural killer cell clones. Science 1995; 267: 1016-1018.
58. Peruzzi M, Wagtmann N, Long EO. A p70 killer cell inhibitory receptor specific for several HLA-B allotypes discriminates among peptides bound to HLA-B*2705. J Exp Med 1996; 184: 1585-1590. (Pubitemid 26354718)
59. Gavioli R, Zhang QJ, Masucci MG. HLA-A11-mediated protection from NK cell-mediated lysis: role of HLA-A11-presented peptides. Hum Immunol 1996; 49: 1-12.
60. Zappacosta F, Borrego F, Brooks AG, Parker KC, Coligan JE. Peptides isolated from HLA-Cw*0304 confer different degrees of protection from natural killer cell-mediated lysis. Proc Natl Acad Sci USA 1997; 94: 6313-6318. (Pubitemid 27270681)
61. Boyington JC, Sun PD. A structural perspective on MHC class I recognition by killer cell immunoglobulin-like receptors. Mol Immunol 2002; 38: 1007-1021. (Pubitemid 34310440)
62. Deng L, Cho S, Malchiodi EL, Kerzic MC, Dam J, Mariuzza RA. Molecular architecture of the major histocompatibility complex class I-binding site of Ly49 natural killer cell receptors. J Biol Chem 2008; 283: 16840-16849.
63. Gardiner CM. Killer cell immunoglobulin-like receptors on NK cells: the how, where and why. Int J Immunogenet 2008; 35: 1-8.
64. Yokoyama WM, Kim S. Licensing of natural killer cells by self-major histocompatibility complex class I. Immunol Rev 2006; 214: 143-154. (Pubitemid 44707908)
65. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005; 436: 709-713. (Pubitemid 41117274)
66. Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006; 25: 331-342. (Pubitemid 44224147)
67. Kim S, Sunwoo JB, Yang L, Choi T, Song YJ, French AR et al. HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci USA 2008; 105: 3053-3058. (Pubitemid 351723666)
68. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002; 100: 1935-1947. (Pubitemid 35001221)
69. Raulet DH, Vance RE, McMahon CW. Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol 2001; 19: 291-330. (Pubitemid 32368038)
70. Gumperz JE, Valiante NM, Parham P, Lanier LL, Tyan D. Heterogeneous phenotypes of expression of the NKB1 natural killer cell class I receptor among individuals of different human histocompatibility leukocyte antigens types appear genetically regulated, but not linked to major histocompatibililty complex haplotype. J Exp Med 1996; 183: 1817-1827.
71. Frohn C, Schlenke P, Kirchner H. The repertoire of HLA-Cw-specific NK cell receptors CD158 a/b (EB6 and GL183) in individuals with different HLA phenotypes. Immunology 1997; 92: 567-570. (Pubitemid 27525230)
72. Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 2002; 20: 217-251. (Pubitemid 34293425)
73. Dupont B, Hsu KC. Inhibitory killer Ig-like receptor genes and human leukocyte antigen class I ligands in haematopoietic stem cell transplantation. Curr Opin Immunol 2004; 16: 634-643. (Pubitemid 39165892)
74. Fernandez NC, Treiner E, Vance RE, Jamieson AM, Lemieux S, Raulet DH. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 2005; 105: 4416-4423. (Pubitemid 40720789)
75. Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med 1998; 187: 813-818. (Pubitemid 28115198)
76. Mingari MC, Ponte M, Bertone S, Schiavetti F, Vitale C, Bellomo R et al. HLA class I-specific inhibitory receptors in human T lymphocytes: interleukin 15-induced expression of CD94/NKG2A in superantigen- or alloantigen-activated CD8+ T cells. Proc Natl Acad Sci USA 1998; 95: 1172-1177. (Pubitemid 28124931)
77. Bertone S, Schiavetti F, Bellomo R, Vitale C, Ponte M, Moretta L et al. Transforming growth factor-beta-induced expression of CD94/NKG2A inhibitory receptors in human T lymphocytes. Eur J Immunol 1999; 29: 23-29. (Pubitemid 29043518)
78. Derre L, Corvaisier M, Pandolfino MC, Diez E, Jotereau F, Gervois N. Expression of CD94/NKG2-A on human T lymphocytes is induced by IL-12: implications for adoptive immunotherapy. J Immunol 2002; 168: 4864-4870. (Pubitemid 34495947)
79. Valiante NM, Uhrberg M, Shilling HG, Lienert-Weidenbach K, Arnett KL, D'Andrea A et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 1997; 7: 739-751. (Pubitemid 28064888)
80. Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998; 391: 795-799. (Pubitemid 28099678)
81. Vance RE, Kraft JR, Altman JD, Jensen PE, Raulet DH. Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1(b). J Exp Med 1998; 188: 1841-1848. (Pubitemid 28536771)
82. Lee N, Goodlett DR, Ishitani A, Marquardt H, Geraghty DE. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J Immunol 1998; 160: 4951-4960. (Pubitemid 28215330)
83. Lanier LL, Corliss B, Wu J, Phillips JH. Association of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity 1998; 8: 693-701. (Pubitemid 28294516)
84. Palmieri G, Tullio V, Zingoni A, Piccoli M, Frati L, Lopez-Botet M et al. CD94/NKG2-A inhibitory complex blocks CD16-triggered Syk and extracellular regulated kinase activation, leading to cytotoxic function of human NK cells. J Immunol 1999; 162: 7181-7188. (Pubitemid 29277689)
85. Carretero M, Cantoni C, Bellon T, Bottino C, Biassoni R, Rodriguez A et al. The CD94 and NKG2-A C-type lectins covalently assemble to form a natural killer cell inhibitory receptor for HLA class I molecules. Eur J Immunol 1997; 27: 563-567. (Pubitemid 27085264)
86. Michaelsson J, Teixeira de Matos C, Achour A, Lanier LL, Karre K, Soderstrom K. A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition. J Exp Med 2002; 196: 1403-1414. (Pubitemid 35424935)
87. Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002; 17: 19-29. (Pubitemid 34874615)
88. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008; 28: 571-580.
89. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727-729.
90. Garrity D, Call ME, Feng J, Wucherpfennig KW. The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. Proc Natl Acad Sci USA 2005; 102: 7641-7646. (Pubitemid 40741024)
91. Diefenbach A, Tomasello E, Lucas M, Jamieson AM, Hsia JK, Vivier E et al. Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat Immunol 2002; 3: 1142-1149. (Pubitemid 35469698)
92. Gilfillan S, Ho EL, Cella M, Yokoyama WM, Colonna M. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat Immunol 2002; 3: 1150-1155. (Pubitemid 35469699)
93. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9: 495-502. (Pubitemid 351560518)
94. McFarland BJ, Strong RK. Thermodynamic analysis of degenerate recognition by the NKG2D immunoreceptor: not induced fit but rigid adaptation. Immunity 2003; 19: 803-812. (Pubitemid 37542301)
95. Jolly C, Morimoto RI. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 2000; 92: 1564-1572.
96. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 1996; 93: 12445-12450. (Pubitemid 26367163)
97. Stern-Ginossar N, Gur C, Biton M, Horwitz E, Elboim M, Stanietsky N et al. Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat Immunol 2008; 9: 1065-1073.
98. Steinle A, Li P, Morris DL, Groh V, Lanier LL, Strong RK et al. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics 2001; 53: 279-287.
99. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001; 14: 123-133. (Pubitemid 32206515)
100. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999; 96: 6879-6884. (Pubitemid 29274978)
101. Jinushi M, Takehara T, Tatsumi T, Kanto T, Groh V, Spies T et al. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int J Cancer 2003; 104: 354-361. (Pubitemid 36249818)
102. Cerwenka A, Bakker AB, McClanahan T, Wagner J, Wu J, Phillips JH et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 2000; 12: 721-727.
103. Carayannopoulos LN, Naidenko OV, Fremont DH, Yokoyama WM. Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D. J Immunol 2002; 169: 4079-4083. (Pubitemid 35178173)
104. Diefenbach A, Hsia JK, Hsiung MY, Raulet DH. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity. Eur J Immunol 2003; 33: 381-391. (Pubitemid 36267602)
105. O'Callaghan CA, Cerwenka A, Willcox BE, Lanier LL, Bjorkman PJ. Molecular competition for NKG2D: H60 and RAE1 compete unequally for NKG2D with dominance of H60. Immunity 2001; 15: 201-211. (Pubitemid 32816870)
106. Hamerman JA, Ogasawara K, Lanier LL. Cutting edge: toll-like receptor signaling in macrophages induces ligands for the NKG2D receptor. J Immunol 2004; 172: 2001-2005. (Pubitemid 38182343)
107. Lodoen M, Ogasawara K, Hamerman JA, Arase H, Houchins JP, Mocarski ES et al. NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. J Exp Med 2003; 197: 1245-1253. (Pubitemid 36617771)
108. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R et al. Regulation of cutaneous malignancy by gammadelta T cells. Science 2001; 294: 605-609. (Pubitemid 32999559)
109. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005; 436: 1186-1190. (Pubitemid 41232299)
110. Nice TJ, Coscoy L, Raulet DH. Posttranslational regulation of the NKG2D ligand Mult1 in response to cell stress. J Exp Med 2009; 206: 287-298.
111. Westwood JA, Kelly JM, Tanner JE, Kershaw MH, Smyth MJ, Hayakawa Y. Cutting edge: novel priming of tumor-specific immunity by NKG2D-triggered NK cell-mediated tumor rejection and Th1-independent CD4+ T cell pathway. J Immunol 2004; 172: 757-761. (Pubitemid 38113730)
112. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419: 734-738. (Pubitemid 35177960)
113. Salih HR, Rammensee HG, Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002; 169: 4098-4102. (Pubitemid 35178177)
114. Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 2003; 100: 4120-4125. (Pubitemid 36418167)
115. Eisele G, Wischhusen J, Mittelbronn M, Meyermann R, Waldhauer I, Steinle A et al. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain 2006; 129: 2416-2425. (Pubitemid 44522126)
116. De Maria A, Ugolotti E, Rutjens E, Mazza S, Radic L, Faravelli A et al. NKp44 expression, phylogenesis and function in non-human primate NK cells. Int Immunol 2009; 21: 245-255.
117. Fuchs A, Cella M, Kondo T, Colonna M. Paradoxic inhibition of human natural interferon-producing cells by the activating receptor NKp44. Blood 2005; 106: 2076-2082. (Pubitemid 41291722)
118. Vitale M, Falco M, Castriconi R, Parolini S, Zambello R, Semenzato G et al. Identification of NKp80, a novel triggering molecule expressed by human NK cells. Eur J Immunol 2001; 31: 233-242.
119. Pende D, Parolini S, Pessino A, Sivori S, Augugliaro R, Morelli L et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999; 190: 1505-1516.
120. Mandelboim O, Porgador A. NKp46. Int J Biochem Cell Biol 2001; 33: 1147-1150. (Pubitemid 32972199)
121. Arnon TI, Lev M, Katz G, Chernobrov Y, Porgador A, Mandelboim O. Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur J Immunol 2001; 31: 2680-2689. (Pubitemid 32898735)
122. Pessino A, Sivori S, Bottino C, Malaspina A, Morelli L, Moretta L et al. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med 1998; 188: 953-960. (Pubitemid 28433421)
123. Hoglund P, Klein E. Natural killer cells in cancer. Semin Cancer Biol 2006; 16: 331-332. (Pubitemid 44311507)
124. Pogge von Strandmann E, Simhadri VR, von Tresckow B, Sasse S, Reiners KS, Hansen HP et al. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 2007; 27: 965-974. (Pubitemid 350251218)
125. Bloushtain N, Qimron U, Bar-Ilan A, Hershkovitz O, Gazit R, Fima E et al. Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. J Immunol 2004; 173: 2392-2401. (Pubitemid 39063095)
126. Welte S, Kuttruff S, Waldhauer I, Steinle A. Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction. Nat Immunol 2006; 7: 1334-1342. (Pubitemid 46111255)
127. Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 2009; 206: 1495-1503.
128. Sivori S, Pende D, Bottino C, Marcenaro E, Pessino A, Biassoni R et al. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur J Immunol 1999; 29: 1656-1666. (Pubitemid 29224471)
129. Halfteck GG, Elboim M, Gur C, Achdout H, Ghadially H, Mandelboim O. Enhanced in vivo growth of lymphoma tumors in the absence of the NK-activating receptor NKp46/NCR1. J Immunol 2009; 182: 2221-2230.
130. Moretta A. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2002; 2: 957-964. (Pubitemid 37323216)
131. Cosman D, Fanger N, Borges L, Kubin M, Chin W, Peterson L et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 1997; 7: 273-282. (Pubitemid 27392018)
132. Colonna M, Navarro F, Bellon T, Llano M, Garcia P, Samaridis J et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 1997; 186: 1809-1818. (Pubitemid 27524591)
133. Shiroishi M, Kuroki K, Rasubala L, Tsumoto K, Kumagai I, Kurimoto E et al. Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d). Proc Natl Acad Sci USA 2006; 103: 16412-16417. (Pubitemid 44715210)
134. Navarro F, Llano M, Bellon T, Colonna M, Geraghty DE, Lopez-Botet M. The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells. Eur J Immunol 1999; 29: 277-283. (Pubitemid 29043545)
135. Chapman TL, Heikeman AP, Bjorkman PJ. The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18. Immunity 1999; 11: 603-613.
136. Leong CC, Chapman TL, Bjorkman PJ, Formankova D, Mocarski ES, Phillips JH et al. Modulation of natural killer cell cytotoxicity in human cytomegalovirus infection: the role of endogenous class I major histocompatibility complex and a viral class I homolog. J Exp Med 1998; 187: 1681-1687. (Pubitemid 28235109)
137. Brown MH, Boles K, van der Merwe PA, Kumar V, Mathew PA, Barclay AN. 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. J Exp Med 1998; 188: 2083-2090. (Pubitemid 28562525)
138. Latchman Y, McKay PF, Reiser H. Identification of the 2B4 molecule as a counter-receptor for CD48. J Immunol 1998; 161: 5809-5812. (Pubitemid 28535943)
139. Garni-Wagner BA, Purohit A, Mathew PA, Bennett M, Kumar V. A novel function-associated molecule related to non-MHC-restricted cytotoxicity mediated by activated natural killer cells and T cells. J Immunol 1993; 151: 60-70. (Pubitemid 23206971)
140. Valiante NM, Trinchieri G. Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes. J Exp Med 1993; 178: 1397-1406. (Pubitemid 23277371)
141. Lee KM, McNerney ME, Stepp SE, Mathew PA, Schatzle JD, Bennett M et al. 2B4 acts as a non-major histocompatibility complex binding inhibitory receptor on mouse natural killer cells. J Exp Med 2004; 199: 1245-1254. (Pubitemid 38620261)
142. McNerney ME, Lee KM, Kumar V. 2B4 (CD244) is a non-MHC binding receptor with multiple functions on natural killer cells and CD8+ T cells. Mol Immunol 2005; 42: 489-494.
143. Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23: 225-274. (Pubitemid 40563170)
144. Mathew SO, Rao KK, Kim JR, Bambard ND, Mathew PA. Functional role of human NK cell receptor 2B4 (CD244) isoforms. Eur J Immunol 2009; 39: 1632-1641.
145. Stepp SE, Schatzle JD, Bennett M, Kumar V, Mathew PA. Gene structure of the murine NK cell receptor 2B4: presence of two alternatively spliced isoforms with distinct cytoplasmic domains. Eur J Immunol 1999; 29: 2392-2399. (Pubitemid 29378107)
146. Schatzle JD, Sheu S, Stepp SE, Mathew PA, Bennett M, Kumar V. Characterization of inhibitory and stimulatory forms of the murine natural killer cell receptor 2B4. Proc Natl Acad Sci USA 1999; 96: 3870-3875. (Pubitemid 29169003)
147. Vaidya SV, Stepp SE, McNerney ME, Lee JK, Bennett M, Lee KM et al. Targeted disruption of the 2B4 gene in mice reveals an in vivo role of 2B4 (CD244) in the rejection of B16 melanoma cells. J Immunol 2005; 174: 800-807. (Pubitemid 40094275)
148. Robbins SH, Nguyen KB, Takahashi N, Mikayama T, Biron CA, Brossay L. Cutting edge: inhibitory functions of the killer cell lectin-like receptor G1 molecule during the activation of mouse NK cells. J Immunol 2002; 168: 2585-2589. (Pubitemid 34211630)
149. Ito M, Maruyama T, Saito N, Koganei S, Yamamoto K, Matsumoto N. Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity. J Exp Med 2006; 203: 289-295. (Pubitemid 43290837)
150. Cowin P, Rowlands TM, Hatsell SJ. Cadherins and catenins in breast cancer. Curr Opin Cell Biol 2005; 17: 499-508. (Pubitemid 41267164)
151. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 2008; 27: 6920-6929.
152. Colonna M. Cytolytic responses: cadherins put out the fire. J Exp Med 2006; 203: 261-264. (Pubitemid 43290834)
153. Lanier LL, Chang C, Phillips JH. Human NKR-P1A. A disulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. J Immunol 1994; 153: 2417-2428. (Pubitemid 24278110)
154. Glimcher L, Shen FW, Cantor H. Identification of a cell-surface antigen selectively expressed on the natural killer cell. J Exp Med 1977; 145: 1-9. (Pubitemid 8010087)
155. Carlyle JR, Martin A, Mehra A, Attisano L, Tsui FW, Zuniga-Pflucker JC. Mouse NKR-P1B, a novel NK1.1 antigen with inhibitory function. J Immunol 1999; 162: 5917-5923. (Pubitemid 29314946)
156. Plougastel B, Dubbelde C, Yokoyama WM. Cloning of Clr, a new family of lectin-like genes localized between mouse Nkrp1a and Cd69. Immunogenetics 2001; 53: 209-214. (Pubitemid 32436939)
157. Arase N, Arase H, Park SY, Ohno H, Ra C, Saito T. Association with FcRgamma is essential for activation signal through NKR-P1 (CD161) in natural killer (NK) cells and NK1.1+ T cells. J Exp Med 1997; 186: 1957-1963. (Pubitemid 28013679)
158. Pozo D, Vales-Gomez M, Mavaddat N, Williamson SC, Chisholm SE, Reyburn H. CD161 (human NKR-P1A) signaling in NK cells involves the activation of acid sphingomyelinase. J Immunol 2006; 176: 2397-2406. (Pubitemid 43201689)
159. Carlyle JR, Jamieson AM, Gasser S, Clingan CS, Arase H, Raulet DH. Missing self-recognition of Ocil/Clr-b by inhibitory NKR-P1 natural killer cell receptors. Proc Natl Acad Sci USA 2004; 101: 3527-3532. (Pubitemid 38338229)
160. Plougastel B, Matsumoto K, Dubbelde C, Yokoyama WM. Analysis of a 1-Mb BAC contig overlapping the mouse Nkrp1 cluster of genes: cloning of three new Nkrp1 members, Nkrp1d, Nkrp1e, and Nkrp1f. Immunogenetics 2001; 53: 592-598. (Pubitemid 33044439)
161. Mesci A, Ljutic B, Makrigiannis AP, Carlyle JR. NKR-P1 biology: from prototype to missing self. Immunol Res 2006; 35: 13-26. (Pubitemid 44547499)
162. Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan T et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 1996; 4: 573-581. (Pubitemid 26233311)
163. Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003; 198: 557-567. (Pubitemid 37040390)
164. Tahara-Hanaoka S, Shibuya K, Onoda Y, Zhang H, Yamazaki S, Miyamoto A et al. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). Int Immunol 2004; 16: 533-538.
165. Masson D, Jarry A, Baury B, Blanchardie P, Laboisse C, Lustenberger P et al. Overexpression of the CD155 gene in human colorectal carcinoma. Gut 2001; 49: 236-240. (Pubitemid 32675118)
166. Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 2009; 113: 3503-3511.
167. Gilfillan S, Chan CJ, Cella M, Haynes NM, Rapaport AS, Boles KS et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med 2008; 205: 2965-2973.
168. Iguchi-Manaka A, Kai H, Yamashita Y, Shibata K, Tahara-Hanaoka S, Honda S et al. Accelerated tumor growth in mice deficient in DNAM-1 receptor. J Exp Med 2008; 205: 2959-2964.
169. Chan CJ, Andrews DM, McLaughlin NM, Yagita H, Gilfillan S, Colonna M et al. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J Immunol 2010; 184: 902-911.
170. Reymond N, Imbert AM, Devilard E, Fabre S, Chabannon C, Xerri L et al. DNAM-1 and PVR regulate monocyte migration through endothelial junctions. J Exp Med 2004; 199: 1331-1341. (Pubitemid 38685725)
171. Shibuya K, Lanier LL, Phillips JH, Ochs HD, Shimizu K, Nakayama E et al. Physical and functional association of LFA-1 with DNAM-1 adhesion molecule. Immunity 1999; 11: 615-623.
172. Barao I, Hudig D, Ascensao JL. IL-15-mediated induction of LFA-1 is a late step required for cytotoxic differentiation of human NK cells from CD34+Lin- bone marrow cells. J Immunol 2003; 171: 683-690. (Pubitemid 36871377)
173. Tassi I, Klesney-Tait J, Colonna M. Dissecting natural killer cell activation pathways through analysis of genetic mutations in human and mouse. Immunol Rev 2006; 214: 92-105. (Pubitemid 44707904)
174. Dardalhon V, Schubart AS, Reddy J, Meyers JH, Monney L, Sabatos CA et al. CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions. J Immunol 2005; 175: 1558-1565. (Pubitemid 41023057)
175. Shibuya K, Shirakawa J, Kameyama T, Honda S, Tahara-Hanaoka S, Miyamoto A et al. CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation. J Exp Med 2003; 198: 1829-1839. (Pubitemid 38032116)
176. Shiratori I, Ogasawara K, Saito T, Lanier LL, Arase H. Activation of natural killer cells and dendritic cells upon recognition of a novel CD99-like ligand by paired immunoglobulin-like type 2 receptor. J Exp Med 2004; 199: 525-533. (Pubitemid 38233836)
177. Mousseau DD, Banville D, L'Abbe D, Bouchard P, Shen SH. PILRalpha, a novel immunoreceptor tyrosine-based inhibitory motif-bearing protein, recruits SHP-1 upon tyrosine phosphorylation and is paired with the truncated counterpart PILRbeta. J Biol Chem 2000; 275: 4467-4474. (Pubitemid 30094691)
178. Wang J, Shiratori I, Satoh T, Lanier LL, Arase H. An essential role of sialylated O-linked sugar chains in the recognition of mouse CD99 by paired Ig-like type 2 receptor (PILR). J Immunol 2008; 180: 1686-1693.